This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
In May President Donald Trump predicted a “massive drops” in drug prices following the signing of the Right-to-Try legislation, as well as a Health and Human Services initiative he called “the most sweeping action in history” to lower the cost of prescription drug prices.
GCVRZ SAN SNYNF SNY
Mylan N.V. (NASDAQ:MYL) has been a battleground stock in 2018. And that’s with good reason, Mylan stock has seen plenty of good news, but also a number of setbacks. EpiPen is a perfect example. The brand brought Mylan shame and a substantial fine, but it’s also in short supply now, continuing to lead to strong ongoing profits.
MYL TEVJF GCVRZ TEVA TEVVF SAN SNYNF GSK SNY
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. Moreover, quite a few negative pipeline and regulatory updates announced this year so far have probably had an unfavorable impact on the industry.
CELGZ AZN IPXL GSK SNY SHPG MRK GCVRZ CELG NVS SAN SNYNF
Though the drug sector was off to a strong start in 2018, it has struggled thereafter probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Moreover, concerns about pressure on drug prices continue to cloud shares of pharma and biotech companies.
CELGZ IPXL GCVRZ CELG CRSP SAN SNYNF SNY AMRX
Still stuck in a trading range, Pfizer Inc. (NYSE:PFE) may continue to drift in either direction after its quarterly earnings report supplied no near-term catalysts. Revenue growing just a percent from last year is uninspiring, while some of the smaller units, like Oncology and Rare Diseases, showed some growth. Pfizer’s drug Viagra coming off patent protection is still the biggest headwind for PFE stock at the moment.
REGN PFZ GCVRZ SAN 500680 SNYNF PFE PFIZER SNY ESRX
Welcome to the Regeneron Pharmaceuticals First Quarter 2018 Earnings Conference Call. My name is Jason and I will be your operator. At this time all participants will be in a listen-only mode. Later, we will have a question-and-answer session. Also, please note this conference is being recorded.
MTZXF REGN MTZPY GCVRZ SAN SNYNF 4508 SNY
(Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
REGN GCVRZ SAN CVS SNYNF SNY
Sanofi and Regeneron have agreed to lower the price of their cholesterol medicine in exchange for easier access for patients covered by pharmacy benefit manager Express Scripts, the first of a number of deals the drugmakers hope to strike to increase use of the medicine.
GCVRZ SAN SNYNF SNY
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
GCVRZ SAN SNYNF SNY
Amazon.com, Alibaba Group Holdings, Visa Inc., Apple Inc., and Taiwan Semiconductor Manufacturing are the largest five individual stock positions.
BNPQY UNLNF LLOBF ABLZF CSCO ABBV GE COF-P VOD HXSCF SCGLY PBR DDAIF AAWW 500180 MSFT NTES HXSCL WST AXP LEN.B COF-D COF-C COF-F HEI FAF RYDAF BIDU TATAMOTORS ASML UL UN LLY GSK DPSGY ICICIBANK HDB GNE TV SSYS VRNT AZN MS.PRE MS.PRF MS.PRG RDSB SIVB RDSA MS.PRA 6506 6503 VSH PEGA CMCSK SAN SMG CAVM SBGSY SMSN VECO PFIZER HEI.A MS.PRI CFRUY MS.PRK KSU.PR RYDBF RJD ABBV PFE RJF SMSD JD COF.PRG HD COF.PRH SSNLF SIEGY SMFG COF.PRP SMFNF GS UBS DG HDFCBANK COF.PRC HSBC COF.PRD ABEV SF.PRA COF.PRF LFUS FANUF SNN CMCSA COST COF LECO TORO SNY V BLK PEP ETFC MRK 532174 LLD5 LLD7 LLD6 LLD1 DPZ LLD2 INGR ULVR BECN YASKY SAN AMX MS 500570 TSM YASKF INFY UTX VCISY BABA MTH NVO JNJ LAZ LLDTF NVS BASFY AZPN BAP CCV LEN WMGI CCZ CLGX BOE AAPL INTC SFTBY KSU BBVA KBH POOL LLOY MA ITUB PACW LVMUY TTC LLPH ING SAP LLPK MEL LLPJ LLPE JPM LLPD 8316 LLPG CCV.CL RHHBY LLPC CRARY 500680 TTM SMCAY BCS XOM CTRP COF.WS SEM WMT AMZN GSK ASML UNLYF SF BC94 WTFCW WTFC STE BBD BRK.A WTFCM GOOGL INFY MKSI BA EWBC PG NTCT YELP HRC GOOG CHE RDY ASX ORCL DIS QRVO PFZ BUD RDS.B GEC RDS.A IBN MIELF SFN LYG UMPQ WTFPP DPSTF ABB AZN MIELY CVX OCLCF SAN SFB
This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here.
GCVRZ SAN SNYNF SNY
April 16 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
BCS.PRD BCS BCS.PRC BCS.PRA GS.PRB GS.PRA 83SF GS GLSSP 83SK GCVRZ 47MC JBK GSC GS.PRICL TFG GSJ SNY GS.PRJ GS.PRI BCS.PR GS.PRD GS.PRC SAN GJS SNYNF GS.PRN GS.PRK
The French economy grew slower than estimated, per the Bank of France, primarily owing to a slowdown in manufacturing activity. The bank’s lower growth estimate for the first quarter is indicative of a somewhat broader slowdown in the Euro zone. European Central Bank (ECB) Executive Board member Benoit Coeure thinks the Euro bloc is witnessing a correction rather than a slowdown, per a Reuters article.
FP BNC GD GCVRZ MBUU SANT SAN SNYNF SAN SNY
European executives are targeting U.S. companies as a brighter economic landscape at home and abroad boosts buyer confidence.
AXAHF CS XL AXJ HSB AXAHY UBS GCVRZ UBS.PRDCL HSBC.PRA HSBC HBCYF HCS.PRB SKG HCS BIVV SNY 0005 HSEA TRI HSEB XLGLF SAN SMFKY QCOM SNYNF ULSGF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to EPA:SAN / SANOFI on message board site Silicon Investor.